{"filing":{"accession_number":"0001193125-26-265861","cik":"0001861123","ticker":"EIKN","company_name":"Eikon Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"eikn-20260605.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526265861/eikn-20260605.htm"},"events":[{"id":5662,"run_id":4964,"accession_number":"0001193125-26-265861","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Ma. Fatima D. Francisco to the Board of Directors as a Class I director, effective June 15, 2026. While the disclosure also includes compensatory arrangements (annual retainer of $50,000 and an option grant of 85,937 shares), the principal action is the appointment itself. The appointment of a new director is material to investors as it affects board composition and governance.","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5870,"accession_number":"0001193125-26-265861","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ma. Fatima D. Francisco to the Board of Directors as a Class I director, effective June 15, 2026. While the disclosure also includes compensatory arrangements (annual retainer of $50,000 and an option grant of 85,937 shares), the principal action is the appointment itself. The appointment of a new director is material to investors as it affects board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:17:38.960438+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5870,"accession_number":"0001193125-26-265861","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ma. Fatima D. Francisco to the Board of Directors as a Class I director, effective June 15, 2026. While the disclosure also includes compensatory arrangements (annual retainer of $50,000 and an option grant of 85,937 shares), the principal action is the appointment itself. The appointment of a new director is material to investors as it affects board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:17:38.960438+00:00","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-06-10"}]}